Alkermes Plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and … Read more
Alkermes Plc (ALKS) - Net Assets
Latest net assets as of December 2025: $1.82 Billion USD
Based on the latest financial reports, Alkermes Plc (ALKS) has net assets worth $1.82 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.53 Billion) and total liabilities ($710.96 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.82 Billion |
| % of Total Assets | 71.9% |
| Annual Growth Rate | 10.89% |
| 5-Year Change | 63.52% |
| 10-Year Change | 50.42% |
| Growth Volatility | 772.63 |
Alkermes Plc - Net Assets Trend (1991–2025)
This chart illustrates how Alkermes Plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Alkermes Plc (1991–2025)
The table below shows the annual net assets of Alkermes Plc from 1991 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.82 Billion | +24.19% |
| 2024-12-31 | $1.46 Billion | +21.81% |
| 2023-12-31 | $1.20 Billion | +15.23% |
| 2022-12-31 | $1.04 Billion | -6.19% |
| 2021-12-31 | $1.11 Billion | +4.27% |
| 2020-12-31 | $1.07 Billion | -1.70% |
| 2019-12-31 | $1.09 Billion | -7.33% |
| 2018-12-31 | $1.17 Billion | -2.62% |
| 2017-12-31 | $1.20 Billion | -0.55% |
| 2016-12-31 | $1.21 Billion | -7.97% |
| 2015-12-31 | $1.31 Billion | -5.91% |
| 2014-12-31 | $1.40 Billion | +31.13% |
| 2013-12-31 | $1.07 Billion | +11.85% |
| 2012-12-31 | $952.37 Million | +11.54% |
| 2011-12-31 | $853.85 Million | +117.81% |
| 2010-12-31 | $392.02 Million | -4.99% |
| 2009-12-31 | $412.62 Million | -1.58% |
| 2008-12-31 | $419.23 Million | +37.31% |
| 2007-12-31 | $305.31 Million | -20.62% |
| 2006-12-31 | $384.65 Million | +100.09% |
| 2005-12-31 | $192.24 Million | +4575.02% |
| 2004-12-31 | $4.11 Million | -78.17% |
| 2003-12-31 | $18.84 Million | -80.94% |
| 2002-12-31 | $98.82 Million | +69.35% |
| 2001-12-31 | $58.35 Million | -51.83% |
| 2000-12-31 | $121.14 Million | -24.93% |
| 1999-12-31 | $161.37 Million | -0.91% |
| 1998-12-31 | $162.85 Million | -2.31% |
| 1997-12-31 | $166.69 Million | +110.60% |
| 1996-12-31 | $79.15 Million | +136.34% |
| 1995-12-31 | $33.49 Million | +57.97% |
| 1994-12-31 | $21.20 Million | -33.54% |
| 1993-12-31 | $31.90 Million | -33.12% |
| 1992-12-31 | $47.70 Million | -11.99% |
| 1991-12-31 | $54.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Alkermes Plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 71679400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.81 Million | 0.10% |
| Other Comprehensive Income | $-2.10 Million | -0.12% |
| Other Components | $2.55 Billion | 140.40% |
| Total Equity | $1.82 Billion | 100.00% |
Alkermes Plc Competitors by Market Cap
The table below lists competitors of Alkermes Plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mueller Water Products
NYSE:MWA
|
$4.26 Billion |
|
Skyline Corporation
NYSE:SKY
|
$4.26 Billion |
|
Ono Pharmaceutical Co. Ltd
PINK:OPHLF
|
$4.26 Billion |
|
Inari Medical Inc
NASDAQ:NARI
|
$4.27 Billion |
|
BB Seguridade Participacoes SA
PINK:BBSEY
|
$4.26 Billion |
|
Iveco Group
OTCGREY:IVCGF
|
$4.26 Billion |
|
MOL Nyrt.
BUD:MOL
|
$4.25 Billion |
|
Hongfa Technology Co Ltd
SHG:600885
|
$4.25 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alkermes Plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,464,977,000 to 1,819,295,000, a change of 354,318,000 (24.2%).
- Net income of 241,664,000 contributed positively to equity growth.
- Share repurchases of 31,032,000 reduced equity.
- Other comprehensive income decreased equity by 133,000.
- Other factors increased equity by 143,819,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $241.66 Million | +13.28% |
| Share Repurchases | $31.03 Million | -1.71% |
| Other Comprehensive Income | $-133.00K | -0.01% |
| Other Changes | $143.82 Million | +7.91% |
| Total Change | $- | 24.19% |
Book Value vs Market Value Analysis
This analysis compares Alkermes Plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.56x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 10.82x to 2.56x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1991-12-31 | $2.55 | $27.65 | x |
| 1992-12-31 | $1.79 | $27.65 | x |
| 1993-12-31 | $1.18 | $27.65 | x |
| 1994-12-31 | $0.72 | $27.65 | x |
| 1995-12-31 | $0.92 | $27.65 | x |
| 1996-12-31 | $1.72 | $27.65 | x |
| 1997-12-31 | $3.39 | $27.65 | x |
| 1998-12-31 | $3.19 | $27.65 | x |
| 1999-12-31 | $2.70 | $27.65 | x |
| 2000-12-31 | $1.90 | $27.65 | x |
| 2001-12-31 | $0.91 | $27.65 | x |
| 2002-12-31 | $1.20 | $27.65 | x |
| 2003-12-31 | $0.21 | $27.65 | x |
| 2004-12-31 | $0.04 | $27.65 | x |
| 2005-12-31 | $1.86 | $27.65 | x |
| 2006-12-31 | $3.74 | $27.65 | x |
| 2007-12-31 | $3.17 | $27.65 | x |
| 2008-12-31 | $4.42 | $27.65 | x |
| 2009-12-31 | $4.32 | $27.65 | x |
| 2010-12-31 | $4.10 | $27.65 | x |
| 2011-12-31 | $6.23 | $27.65 | x |
| 2012-12-31 | $6.95 | $27.65 | x |
| 2013-12-31 | $7.35 | $27.65 | x |
| 2014-12-31 | $9.62 | $27.65 | x |
| 2015-12-31 | $8.81 | $27.65 | x |
| 2016-12-31 | $7.98 | $27.65 | x |
| 2017-12-31 | $7.84 | $27.65 | x |
| 2018-12-31 | $7.55 | $27.65 | x |
| 2019-12-31 | $6.91 | $27.65 | x |
| 2020-12-31 | $6.72 | $27.65 | x |
| 2021-12-31 | $6.91 | $27.65 | x |
| 2022-12-31 | $6.37 | $27.65 | x |
| 2023-12-31 | $7.09 | $27.65 | x |
| 2024-12-31 | $8.66 | $27.65 | x |
| 2025-12-31 | $10.78 | $27.65 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Alkermes Plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.28%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.37%
- • Asset Turnover: 0.58x
- • Equity Multiplier: 1.39x
- Recent ROE (13.28%) is above the historical average (-28.51%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1991 | -73.99% | -422.11% | 0.17x | 1.03x | $-45.52 Million |
| 1992 | -36.27% | -221.79% | 0.14x | 1.13x | $-22.07 Million |
| 1993 | -37.30% | -96.75% | 0.27x | 1.45x | $-15.09 Million |
| 1994 | -64.84% | -86.36% | 0.43x | 1.73x | $-15.87 Million |
| 1995 | -56.13% | -94.81% | 0.34x | 1.72x | $-22.15 Million |
| 1996 | -15.90% | -40.11% | 0.30x | 1.32x | $-20.50 Million |
| 1997 | -24.66% | -121.24% | 0.15x | 1.32x | $-57.77 Million |
| 1998 | -41.79% | -296.89% | 0.11x | 1.31x | $-84.33 Million |
| 1999 | -10.45% | -30.11% | 0.14x | 2.50x | $-33.01 Million |
| 2000 | -50.65% | -113.41% | 0.14x | 3.19x | $-73.47 Million |
| 2001 | -183.19% | -226.16% | 0.16x | 4.99x | $-112.73 Million |
| 2002 | -103.60% | -262.16% | 0.13x | 3.00x | $-112.27 Million |
| 2003 | -398.98% | -98.74% | 0.38x | 10.71x | $-77.05 Million |
| 2004 | 92.85% | 2.29% | 0.49x | 82.41x | $3.41 Million |
| 2005 | 4.91% | 3.94% | 0.43x | 2.93x | $-9.78 Million |
| 2006 | 43.41% | 69.37% | 0.33x | 1.90x | $128.51 Million |
| 2007 | 42.74% | 39.93% | 0.50x | 2.15x | $99.97 Million |
| 2008 | -9.45% | -22.23% | 0.34x | 1.24x | $-81.55 Million |
| 2009 | -11.04% | -24.40% | 0.36x | 1.25x | $-86.80 Million |
| 2010 | -29.00% | -29.15% | 0.86x | 1.15x | $-152.88 Million |
| 2011 | 2.93% | 4.34% | 0.40x | 1.68x | $-60.40 Million |
| 2012 | 2.62% | 4.34% | 0.39x | 1.54x | $-70.25 Million |
| 2013 | 1.65% | 4.07% | 0.27x | 1.48x | $-88.92 Million |
| 2014 | -2.15% | -4.86% | 0.32x | 1.38x | $-169.74 Million |
| 2015 | -17.28% | -36.15% | 0.34x | 1.41x | $-358.59 Million |
| 2016 | -17.23% | -27.95% | 0.43x | 1.43x | $-329.39 Million |
| 2017 | -13.13% | -17.48% | 0.50x | 1.49x | $-278.23 Million |
| 2018 | -11.89% | -12.73% | 0.60x | 1.56x | $-256.44 Million |
| 2019 | -18.11% | -16.79% | 0.65x | 1.66x | $-305.16 Million |
| 2020 | -10.39% | -10.67% | 0.53x | 1.83x | $-217.56 Million |
| 2021 | -4.33% | -4.10% | 0.58x | 1.82x | $-159.43 Million |
| 2022 | -15.16% | -14.24% | 0.57x | 1.88x | $-262.64 Million |
| 2023 | 29.58% | 21.39% | 0.78x | 1.78x | $235.49 Million |
| 2024 | 25.06% | 23.57% | 0.76x | 1.40x | $220.57 Million |
| 2025 | 13.28% | 16.37% | 0.58x | 1.39x | $59.73 Million |
Industry Comparison
This section compares Alkermes Plc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Alkermes Plc (ALKS) | $1.82 Billion | -73.99% | 0.39x | $4.26 Billion |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |